CAJ | 학술논문

目的探讨瑞波西汀和马普替林治疗伴有焦虑症状的抑郁症的疗效与安全性.方法将69例伴有焦虑症状的抑郁症患者随机分为瑞波西汀组35例和马普替林组34例.观察6周,于治疗前和治疗后1、2、4及6周末采用汉密尔顿抑郁量表及汉密顿焦虑量表评定其疗效,用不良反应量表评定其不良反应.结果瑞波西汀组的显效率为80％,马普替林组的显效率为79％,瑞波西汀组不良反应相对较少.结论瑞波西汀治疗抑郁症疗效较好,且起效快,不良反应少.
목적 탐토서파서정화마보체림치료반유초필증상적억욱증적료효여안전성.방법 장69례반유초필증상적억욱증환자수궤분위서파서정조35례화마보체림조34례.관찰6주,우치료전화치료후1、2、4급6주말채용한밀이돈억욱량표급한밀돈초필량표평정기료효,용불량반응량표평정기불량반응.결과 서파서정조적현효솔위80％,마보체림조적현효솔위79％,서파서정조불량반응상대교소.결론 서파서정치료억욱증료효교호,차기효쾌,불량반응소.
Objective To investigate the efficacy and safety of fluvoxamine in the treatment of patients with refractory depression and anxiety.Methods Sixty -nine patients with refractory depression and anxiety were randomly assigned to 6 weeks treatment with fluvoxamine (n =35 )or maprotiline (n =34 ) and changes from baseline in the Hamilton Rating Scale for Depression( HAMD - 17),total scores of the two groups,and Treatment Emergent Symptom Scale (TESS)were compared at 1 week before treatment and 1,2,4,6 weeks after treatment.Results The significant efficacy rates of fluvoxamine group was 78％,while that was 75％ in the maprotiline group.There were less side effects in the fluvoxamine group than maprotiline group.Conclusions Fluvoxamine is better than maprotiline in the treatment of refractory depression and anxiety,It shows better efficacy and less side effects.It is beneficial to improve the herapeutic compliance of depressive patients.